These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12608469)

  • 21. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans.
    Hara M; Han M
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3333-7. PubMed ID: 7536929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A significant role of lipogenic enzymes in colorectal cancer.
    Notarnicola M; Messa C; Caruso MG
    Anticancer Res; 2012 Jul; 32(7):2585-90. PubMed ID: 22753716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ras oncogene activation in benign and malignant colorectal tumours.
    Spandidos DA; Glarakis IS; Kotsinas A; Ergazaki M; Kiaris H
    Tumori; 1995; 81(3 Suppl):7-11. PubMed ID: 7571058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced MGMT activity in human colorectal adenomas is associated with K-ras GC->AT transition mutations in a population exposed to methylating agents.
    Lees NP; Harrison KL; Hall CN; Margison GP; Povey AC
    Carcinogenesis; 2004 Jul; 25(7):1243-7. PubMed ID: 14963016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor.
    Russo P; Arzani D; Trombino S; Falugi C
    J Pharmacol Exp Ther; 2003 Jan; 304(1):37-47. PubMed ID: 12490573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas.
    Yatabe Y; Koga T; Mitsudomi T; Takahashi T
    J Pathol; 2004 Jun; 203(2):645-52. PubMed ID: 15141379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
    Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
    J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients.
    Akkiprik M; Celikel CA; Düşünceli F; Sönmez O; Güllüoğlu BM; Sav A; Ozer A
    Turk J Gastroenterol; 2008 Mar; 19(1):22-7. PubMed ID: 18386236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and clinico-pathological associations of ras mutations in colorectal cancer in the Victorian population.
    Thomas RJ; Liu YS; St Clair F; Norris PM; Valentine R; Phillips WA
    Aust N Z J Surg; 1997 May; 67(5):233-8. PubMed ID: 9152150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease.
    Borchers R; Heinzlmann M; Zahn R; Witter K; Martin K; Loeschke K; Folwaczny C
    Scand J Gastroenterol; 2002 Jun; 37(6):715-8. PubMed ID: 12126252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis.
    Minamoto T; Yamashita N; Ochiai A; Mai M; Sugimura T; Ronai Z; Esumi H
    Cancer; 1995 Mar; 75(6 Suppl):1520-6. PubMed ID: 7889485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas.
    Minamoto T; Sawaguchi K; Mai M; Yamashita N; Sugimura T; Esumi H
    Cancer Res; 1994 Jun; 54(11):2841-4. PubMed ID: 8187064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration.
    Yoshitake N; Fujii S; Mukawa K; Tominaga K; Fukui H; Ichikawa K; Tomita S; Ono Y; Imai Y; Terano A; Hiraishi H; Fujimori T
    Oncol Rep; 2007 Jan; 17(1):9-15. PubMed ID: 17143472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer.
    Tai CJ; Chang CC; Jiang MC; Yeh CM; Su TC; Wu PR; Chen CJ; Yeh KT; Lin SH; Chen HC
    Pol J Pathol; 2012 Jun; 63(2):93-100. PubMed ID: 22864777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of tumour DNA in serum of colorectal cancer patients.
    de Kok JB; van Solinge WW; Ruers TJ; Roelofs RW; van Muijen GN; Willems JL; Swinkels DW
    Scand J Clin Lab Invest; 1997 Nov; 57(7):601-4. PubMed ID: 9397491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces.
    Ratto C; Flamini G; Sofo L; Nucera P; Ippoliti M; Curigliano G; Ferretti G; Sgambato A; Merico M; Doglietto GB; Cittadini A; Crucitti F
    Dis Colon Rectum; 1996 Nov; 39(11):1238-44. PubMed ID: 8918432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer.
    Iinuma H; Okinaga K; Adachi M; Suda K; Sekine T; Sakagawa K; Baba Y; Tamura J; Kumagai H; Ida A
    Int J Cancer; 2000 Jul; 89(4):337-44. PubMed ID: 10956407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of K-Ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma.
    Etoh T; Ueo H; Inoue H; Sato K; Utsunomiya T; Barnard GF; Kitano S; Mori M
    Ann Surg Oncol; 2001 Jun; 8(5):407-12. PubMed ID: 11407514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
    Wang JY; Hsieh JS; Chang MY; Huang TJ; Chen FM; Cheng TL; Alexandersen K; Huang YS; Tzou WS; Lin SR
    World J Surg; 2004 Jul; 28(7):721-6. PubMed ID: 15185002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.